Evidence map›Paper›PMID 38152621›Full record

ReviewTurkish journal of biology = Turk biyoloji dergisi2023

Antioxidant potential of nanomaterials.

David González-Flores, Javier Espino, José Antonio Pariente

Abstract readReview
In one paragraph

Review in Turkish journal of biology = Turk biyoloji dergisi, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David González-FloresDepartment of Anatomy, Cell Biology and Zoology, Faculty of Sciences, University of Extremadura, Badajoz, Spain.ORCID https://orcid.org/0000-0002-4543-8810
Javier EspinoDepartment of Physiology, Faculty of Sciences, University of Extremadura, Badajoz, Spain.ORCID https://orcid.org/0000-0002-8549-9343
José Antonio ParienteDepartment of Physiology, Faculty of Sciences, University of Extremadura, Badajoz, Spain.ORCID https://orcid.org/0000-0002-9094-9943

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: The novel field of nanomaterials allows infinite possibilities in order to create antioxidant therapies. The present review is aimed to describe the state of art concerning on nanomaterials and their effects on reactive oxygen species (ROS) production. A wide range of nanoparticles has been designed for this purpose, and each one possesses some particular characteristics which allow these significant antioxidant results. Several in vivo and in vitro works state the ability of these nanoparticles to mimic the redox systems of the cells, and thus, the potential role of nanoparticles as antioxidant treatment for several diseases. Materials and methods: This paper was written after a review of the articles published on the field, using the "PubMed" and "Research Gate" databases. Results: The main types of nanoparticles are listed and explained below, offering a global vision of the field with great interest for research. Antitumor chemo- and radiotherapies have been found to improve efficacy by enhancing the selectivity of cytocidal effects and minimizing systemic adverse effects when such materials are used. Furthermore, catalytic nanomaterials can execute energy-free antioxidant cycles that scavenge the most harmful reactive oxygen species via SOD- and catalase-like activities. Conclusion: This unique method is projected to result in significant gains in the long run. However, due to a lack of understanding of potential adverse body reactions to these novel strategies, caution must be exercised. Analyzing the biocompatibility of these nanomaterials carefully, particularly in terms of biokinetics and the problems that could arise from long-term retention of nonbiodegradable inorganic nanomaterials, is required.

Indexed as

antioxidantnanomaterialoxidative stressReactive oxygen species

Identifiers

PMID38152621
PMCPMC10751091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.